Responsiveness of impairments and disabilities in Parkinson's disease.
暂无分享,去创建一个
A M Stiggelbout | A. Stiggelbout | J. Marinus | J. J. van Hilten | M. Visser | J J van Hilten | J Marinus | M Visser | J. V. van Hilten
[1] R. Marconi,et al. Pergolide monotherapy in the treatment of early PD , 1999, Neurology.
[2] M H Liang,et al. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. , 1985, Arthritis and rheumatism.
[3] D. Streiner,et al. Health Measurement Scales: A practical guide to thier development and use , 1989 .
[4] L. D. de Witte,et al. Assessing the responsiveness of a functional status measure: the Sickness Impact Profile versus the SIP68. , 1997, Journal of clinical epidemiology.
[5] J. Hubble,et al. Pramipexole in patients with early Parkinson's disease. , 1995, Clinical neuropharmacology.
[6] S. Leurgans,et al. Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[7] D. Beaton,et al. Understanding the relevance of measured change through studies of responsiveness. , 2000, Spine.
[8] S. Leurgans,et al. Objective changes in motor function during placebo treatment in PD , 2000, Neurology.
[9] P. Martínez-Martín,et al. Unified Parkinson's disease rating scale characteristics and structure , 1994, Movement disorders : official journal of the Movement Disorder Society.
[10] S Fahn,et al. Freezing of gait in PD , 2001, Neurology.
[11] A. Bonnet. Involvement of Non-Dopaminergic Pathways in Parkinson’s Disease , 2000 .
[12] A. H. Zwinderman,et al. Rating impairment and disability in Parkinson's disease: Evaluation of the unified Parkinson's disease rating scale , 1994, Movement disorders : official journal of the Movement Disorder Society.
[13] I Litvan,et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. , 2001, Archives of neurology.
[14] A. Zwinderman,et al. Influence of dopaminergic medication on automatic postural responses and balance impairment in Parkinson's disease , 1996, Movement disorders : official journal of the Movement Disorder Society.
[15] S. Fahn. Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .
[16] J. Lakke. Axial apraxia in Parkinson's disease , 1985, Journal of the Neurological Sciences.
[17] P. Lachenbruch. Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .
[18] C. Adler,et al. Ropinirole for the treatment of early Parkinson's disease , 1997, Neurology.
[19] S. Fahn. Unified Parkinson's Disease Rating Scale , 1987 .
[20] F. Vingerhoets,et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? , 1997, Annals of neurology.
[21] R. Elble. Tremor and dopamine agonists , 2002, Neurology.
[22] K. Marder,et al. Progression of parkinsonian signs in Parkinson disease. , 1999, Archives of neurology.
[23] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[24] Pablo Martínez-Martín,et al. Patients', doctors', and caregivers' assessment of disability using the UPDRS‐ADL section: Are these ratings interchangeable? , 2003, Movement disorders : official journal of the Movement Disorder Society.
[25] M Richards,et al. Interrater reliability of the unified Parkinson's disease rating scale motor examination , 1994, Movement disorders : official journal of the Movement Disorder Society.
[26] R. Walker,et al. Incidence and prediction of falls in Parkinson's disease: a prospective multidisciplinary study , 2002, Journal of neurology, neurosurgery, and psychiatry.
[27] M. Liang,et al. Comparisons of Five Health Status Instruments for Orthopedic Evaluation , 1990, Medical care.
[28] G. Stebbins,et al. Factor structure of the unified Parkinson's disease rating scale: Motor examination section , 1998, Movement disorders : official journal of the Movement Disorder Society.
[29] Jacob Cohen. Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.
[30] A. Siderowf,et al. Test–Retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial , 2002, Movement disorders : official journal of the Movement Disorder Society.
[31] O. Rascol,et al. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. , 1998, Clinical neuropharmacology.
[32] A. Stiggelbout,et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.